Arovella Therapeutics Ltd (ALA) - Net Assets

Latest as of December 2025: AU$18.92 Million AUD ≈ $13.39 Million USD

Based on the latest financial reports, Arovella Therapeutics Ltd (ALA) has net assets worth AU$18.92 Million AUD (≈ $13.39 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$20.25 Million ≈ $14.33 Million USD) and total liabilities (AU$1.33 Million ≈ $940.32K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALA financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$18.92 Million
% of Total Assets 93.44%
Annual Growth Rate 5.08%
5-Year Change 123.52%
10-Year Change 20.89%
Growth Volatility 77.71

Arovella Therapeutics Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Arovella Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore ALA asset base for the complete picture of this company's asset base.

Annual Net Assets for Arovella Therapeutics Ltd (2001–2025)

The table below shows the annual net assets of Arovella Therapeutics Ltd from 2001 to 2025. For live valuation and market cap data, see ALA market cap.

Year Net Assets Change
2025-06-30 AU$20.08 Million
≈ $14.21 Million		 +78.80%
2024-06-30 AU$11.23 Million
≈ $7.94 Million		 +197.03%
2023-06-30 AU$3.78 Million
≈ $2.67 Million		 -50.37%
2022-06-30 AU$7.62 Million
≈ $5.39 Million		 -15.19%
2021-06-30 AU$8.98 Million
≈ $6.36 Million		 +117.19%
2020-06-30 AU$4.14 Million
≈ $2.93 Million		 -70.41%
2019-06-30 AU$13.98 Million
≈ $9.89 Million		 +21.92%
2018-06-30 AU$11.46 Million
≈ $8.11 Million		 -31.97%
2017-06-30 AU$16.85 Million
≈ $11.92 Million		 +1.48%
2016-06-30 AU$16.61 Million
≈ $11.75 Million		 -13.96%
2015-06-30 AU$19.30 Million
≈ $13.66 Million		 +20.69%
2014-06-30 AU$15.99 Million
≈ $11.32 Million		 +139.03%
2013-06-30 AU$6.69 Million
≈ $4.73 Million		 -4.59%
2012-06-30 AU$7.01 Million
≈ $4.96 Million		 -36.44%
2011-06-30 AU$11.03 Million
≈ $7.81 Million		 +32.19%
2010-06-30 AU$8.35 Million
≈ $5.91 Million		 -5.62%
2009-06-30 AU$8.84 Million
≈ $6.26 Million		 -15.87%
2008-06-30 AU$10.51 Million
≈ $7.44 Million		 -26.65%
2007-06-30 AU$14.33 Million
≈ $10.14 Million		 +7.31%
2006-06-30 AU$13.35 Million
≈ $9.45 Million		 +13.88%
2005-06-30 AU$11.72 Million
≈ $8.30 Million		 -11.68%
2004-06-30 AU$13.27 Million
≈ $9.39 Million		 +252.38%
2003-06-30 AU$3.77 Million
≈ $2.67 Million		 +25.66%
2002-06-30 AU$3.00 Million
≈ $2.12 Million		 -50.96%
2001-06-30 AU$6.11 Million
≈ $4.33 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Arovella Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 10238602300.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$120.13 Million 598.37%
Other Comprehensive Income AU$2.79 Million 13.87%
Total Equity AU$20.08 Million 100.00%

Arovella Therapeutics Ltd Competitors by Market Cap

The table below lists competitors of Arovella Therapeutics Ltd ranked by their market capitalization.

Company Market Cap
PW Consolidated Bhd
KLSE:7134
 $58.09 Million
Edelteq Holdings Berhad
KLSE:0278
 $58.09 Million
Chang Type Industrial Co Ltd
TW:1541
 $58.09 Million
EstechPharma Co. Ltd
KQ:041910
 $58.10 Million
ADVENICA AB
F:65R
 $58.07 Million
Hyundai HT CoLtd
KQ:039010
 $58.07 Million
Articore Group Ltd
AU:ATG
 $58.07 Million
An-Shin Food Services Co Ltd
TWO:1259
 $58.06 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Arovella Therapeutics Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 11,228,047 to 20,076,003, a change of 8,847,956 (78.8%).
  • Net loss of 7,509,166 reduced equity.
  • Share repurchases of 1,287,503 reduced equity.
  • New share issuances of 16,809,895 increased equity.
  • Other comprehensive income increased equity by 347,486.
  • Other factors increased equity by 487,244.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-7.51 Million -37.4%
Share Repurchases AU$1.29 Million -6.41%
Share Issuances AU$16.81 Million +83.73%
Other Comprehensive Income AU$347.49K +1.73%
Other Changes AU$487.24K +2.43%
Total Change AU$- 78.80%

Book Value vs Market Value Analysis

This analysis compares Arovella Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.72x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.07x to 3.72x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-06-30 AU$0.99 AU$0.07 x
2002-06-30 AU$0.63 AU$0.07 x
2003-06-30 AU$0.70 AU$0.07 x
2004-06-30 AU$1.91 AU$0.07 x
2005-06-30 AU$1.58 AU$0.07 x
2006-06-30 AU$1.70 AU$0.07 x
2007-06-30 AU$1.60 AU$0.07 x
2008-06-30 AU$0.97 AU$0.07 x
2009-06-30 AU$0.82 AU$0.07 x
2010-06-30 AU$0.43 AU$0.07 x
2011-06-30 AU$0.43 AU$0.07 x
2012-06-30 AU$0.20 AU$0.07 x
2013-06-30 AU$0.20 AU$0.07 x
2014-06-30 AU$0.31 AU$0.07 x
2015-06-30 AU$0.31 AU$0.07 x
2016-06-30 AU$0.36 AU$0.07 x
2017-06-30 AU$0.27 AU$0.07 x
2018-06-30 AU$0.17 AU$0.07 x
2019-06-30 AU$0.12 AU$0.07 x
2020-06-30 AU$0.02 AU$0.07 x
2021-06-30 AU$0.03 AU$0.07 x
2022-06-30 AU$0.01 AU$0.07 x
2023-06-30 AU$0.01 AU$0.07 x
2024-06-30 AU$0.01 AU$0.07 x
2025-06-30 AU$0.02 AU$0.07 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Arovella Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -37.40%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -5521.45%
  • • Asset Turnover: 0.01x
  • • Equity Multiplier: 1.08x
  • Recent ROE (-37.40%) is above the historical average (-54.35%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 -1.30% 0.00% 0.00x 1.00x AU$-690.54K
2002 -25.05% 0.00% 0.00x 1.05x AU$-1.05 Million
2003 -28.27% -756.50% 0.03x 1.24x AU$-1.44 Million
2004 -7.29% -20.39% 0.29x 1.21x AU$-2.30 Million
2005 -16.45% -23.60% 0.55x 1.28x AU$-3.10 Million
2006 -1.99% -3.19% 0.50x 1.25x AU$-1.60 Million
2007 -12.38% -18.65% 0.45x 1.47x AU$-3.21 Million
2008 -89.63% -77.59% 0.74x 1.57x AU$-10.23 Million
2009 -33.96% -15515.69% 0.00x 1.88x AU$-3.89 Million
2010 -58.19% -34163.29% 0.00x 1.43x AU$-5.69 Million
2011 -40.87% -150.11% 0.22x 1.23x AU$-5.61 Million
2012 -65.53% -117.55% 0.40x 1.39x AU$-5.30 Million
2013 -24.93% -41.22% 0.38x 1.60x AU$-2.34 Million
2014 -14.71% -23.73% 0.43x 1.46x AU$-3.45 Million
2015 -19.50% -59.86% 0.25x 1.32x AU$-5.09 Million
2016 -13.43% -38.56% 0.30x 1.18x AU$-3.89 Million
2017 -7.35% -17.15% 0.36x 1.19x AU$-2.92 Million
2018 -47.62% -1281.93% 0.03x 1.45x AU$-6.61 Million
2019 -55.77% -639.42% 0.08x 1.16x AU$-9.19 Million
2020 -240.46% -1866.73% 0.08x 1.62x AU$-10.36 Million
2021 -56.20% -1961.35% 0.02x 1.19x AU$-5.95 Million
2022 -113.18% -2914.23% 0.03x 1.21x AU$-9.38 Million
2023 -269.34% -2508.35% 0.07x 1.45x AU$-10.56 Million
2024 -77.89% -51447.26% 0.00x 1.18x AU$-9.87 Million
2025 -37.40% -5521.45% 0.01x 1.08x AU$-9.52 Million

Industry Comparison

This section compares Arovella Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $9,674,997
  • Average return on equity (ROE) among peers: -74.42%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Arovella Therapeutics Ltd (ALA) AU$18.92 Million -1.30% 0.07x $58.08 Million
Adalta Ltd (1AD) $3.70 Million -162.25% 0.87x $6.50 Million
Algorae Pharmaceuticals Ltd (1AI) $-1.33 Million 0.00% 0.00x $20.04 Million
ACRUX Ltd (ACR) $12.85 Million -73.71% 0.44x $3.20 Million
Actinogen Medical Ltd (ACW) $21.74 Million -43.69% 0.07x $105.70 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $15.45 Million
Anatara Lifesciences Ltd (ANR) $924.54K -218.83% 0.54x $1.57 Million
Alterity Therapeutics Ltd (ATH) $20.73 Million -6.40% 0.01x $76.95 Million
Amplia Therapeutics Ltd (ATX) $11.23 Million -30.16% 0.02x $50.82 Million
Avecho Biotechnology Ltd (AVE) $3.27 Million -95.48% 0.53x $28.59 Million

About Arovella Therapeutics Ltd

AU:ALA Australia Biotechnology
Market Cap
$58.08 Million
AU$82.09 Million AUD
Market Cap Rank
#21314 Global
#753 in Australia
Share Price
AU$0.07
Change (1 day)
-2.86%
52-Week Range
AU$0.07 - AU$0.12
All Time High
AU$0.57
Categories
Companies in Australia Biotechnology
About

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more